1h Free Analyst Time
Global Conjugate Vaccines Market: About this marketSpeak directly to the analyst to clarify any post sales queries you may have.
The conjugate vaccines market analysis considers sales from the multivalent conjugate vaccine and monovalent conjugate vaccine types. Our study also finds the sales of conjugate vaccines in Asia, Europe, North America, and ROW. In 2019, the multivalent conjugate vaccine segment had a significant market share, and this trend is expected to continue over the forecast period. Factors such as the prevention of diphtheria, tetanus, pertussis, poliomyelitis, hepatitis B, and invasive diseases will play a significant role in the multivalent conjugate vaccine segment to maintain its market position. Also, our global conjugate vaccines market report looks at factors such as increased funding for vaccine development, awareness about immunization programs and access to vaccines, and approval and regulatory incentives for conjugated vaccines. However, high costs associated with vaccine research, development, and manufacturing, safety concerns associated with conjugate vaccines, and challenges in development and global implementation of conjugate vaccines hamper the growth of the conjugate vaccines industry over the forecast period.
Global Conjugate Vaccines Market: Overview
Increasing awareness about immunization programs and access to vaccines
Initiatives aimed at increasing the awareness about well recognized and successful public health immunization programs are promoting the overall vaccine coverage around the globe. For instance, World Pneumonia Day is celebrated every year on November 12 to lower the incidence of pneumonia and reduce the resultant mortality rate. Similarly, other programs are focusing on improving drug delivery and diagnostics to address the health issues in low and middle-income countries. Such initiatives targeted towards boosting access to vaccines will drive the demand for conjugate vaccines. Conjugate vaccines are developed to immunize against a single antigen or two or more strains of the same microorganism. Thus, the promotion of immunization programs will lead to the expansion of the global conjugate vaccines market at a CAGR of over 9% during the forecast period.
Increasing efforts for stockpiling of conjugate vaccines
Governments are putting efforts to store vaccines in bulk to combat future emergency outbreaks of infectious diseases. For instance, The United Nations Children's Fund (UNICEF) works in collaboration with several public and private organizations to procure vaccines to combat future emergency outbreaks of infectious diseases. Furthermore, the International Coordinating Group (ICG) on Vaccine Provisions for Epidemic Meningitis Control also unites several public and private organizations to support emergency health programs and disease outbreak programs. The ongoing efforts in this area are expected to present significant growth opportunities for the existing vendors to meet the unmet demand for meningococcal conjugate vaccines, which will support the growth of the market during the forecast period.
Competitive Landscape
With the presence of a few major players, the global conjugate vaccines market is concentrated. The robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of few leading conjugate vaccines manufacturers, that include Aurobindo Pharma Ltd., GlaxoSmithKline Plc, Integrated Biotherapeutics Inc., Merck & Co. Inc., Mitsubishi Tanabe Pharma Corp., Pfenex Inc., Pfizer Inc., Sanofi, Serum Institute of India Pvt. Ltd., and Sun Pharmaceutical Industries Ltd.
Also, the conjugate vaccines market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage on all forthcoming growth opportunities.
Table of Contents
PART 01: EXECUTIVE SUMMARYPART 07: CUSTOMER LANDSCAPEPART 09: DECISION FRAMEWORK
PART 02: SCOPE OF THE REPORT
PART 03: MARKET LANDSCAPE
PART 04: MARKET SIZING
PART 05: FIVE FORCES ANALYSIS
PART 06: MARKET SEGMENTATION BY TYPE
PART 08: GEOGRAPHIC LANDSCAPE
PART 10: DRIVERS AND CHALLENGES
PART 11: MARKET TRENDS
PART 12: VENDOR LANDSCAPE
PART 13: VENDOR ANALYSIS
PART 14: APPENDIX
List of Exhibits
Executive Summary
The following companies as the key players in the global conjugate vaccines market: Aurobindo Pharma Ltd., GlaxoSmithKline Plc, Integrated Biotherapeutics Inc., Merck & Co. Inc., Mitsubishi Tanabe Pharma Corp., Pfenex Inc., Pfizer Inc., Sanofi, Serum Institute of India Pvt. Ltd., and Sun Pharmaceutical Industries Ltd.Commenting on the report, an analyst from the research team said: “The latest trend gaining momentum in the market is the emergence of strategies to improve conjugate vaccine manufacturing.”
According to the report, one of the major drivers for this market is the increasing awareness about immunization programs and access to vaccines.
Further, the report states that one of the major factors hindering the growth of this market is the challenges in the development and global implementation of conjugate vaccines.
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Aurobindo Pharma Ltd.
- GlaxoSmithKline Plc
- Integrated Biotherapeutics Inc.
- Merck & Co. Inc.
- Mitsubishi Tanabe Pharma Corp.
- Pfenex Inc.
- Pfizer Inc.
- Sanofi
- Serum Institute of India Pvt. Ltd.
- Sun Pharmaceutical Industries Ltd.
